+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Integrin Alpha V"

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 - Product Thumbnail Image

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 86 Pages
  • Global
From
Integrin Alpha V Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Integrin Alpha V Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 90 Pages
  • Global
From
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018 - Product Thumbnail Image

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 57 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Integrin Alpha V is a type of integrin, a family of proteins that play a role in cell adhesion and migration. In the context of oncology drugs, Integrin Alpha V is a target for the development of therapies to treat cancer. It is believed that blocking the activity of Integrin Alpha V can help to reduce the spread of cancer cells and the formation of new blood vessels that feed tumors. Integrin Alpha V is being studied in combination with other drugs to treat a variety of cancers, including breast, ovarian, and lung cancer. Several companies are developing drugs targeting Integrin Alpha V, including AstraZeneca, Merck, and Novartis. Additionally, several biotechnology companies are researching and developing Integrin Alpha V-targeting drugs, such as AbbVie, Amgen, and Gilead Sciences. Show Less Read more